MML Investors Services’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,497
| Closed | -$205K | – | 3132 |
|
|
2025
Q4 | $205K | Buy |
+2,497
| New | +$193K | ﹤0.01% | 2868 |
|
|
2025
Q1 | – | Sell |
-3,091
| Closed | -$206K | – | 2774 |
|
|
2024
Q4 | $206K | Sell |
3,091
-530
| -15% | -$36.5K | ﹤0.01% | 2502 |
|
|
2024
Q3 | $253K | Sell |
3,621
-351
| -9% | -$24.3K | ﹤0.01% | 2286 |
|
|
2024
Q2 | $257K | Sell |
3,972
-219
| -5% | -$13.9K | ﹤0.01% | 2189 |
|
|
2024
Q1 | $271K | Sell |
4,191
-399
| -9% | -$26K | ﹤0.01% | 2177 |
|
|
2023
Q4 | $302K | Sell |
4,590
-302
| -6% | -$17.6K | ﹤0.01% | 2042 |
|
|
2023
Q3 | $279K | Hold |
4,892
| – | – | ﹤0.01% | 1972 |
|
|
2023
Q2 | $300K | Buy |
4,892
+219
| +5% | +$13.7K | ﹤0.01% | 1942 |
|
|
2023
Q1 | $293K | Hold |
4,673
| – | – | ﹤0.01% | 1689 |
|
|
2022
Q4 | $297K | Hold |
4,673
| – | – | ﹤0.01% | 1786 |
|
|
2022
Q3 | $275K | Hold |
4,673
| – | – | ﹤0.01% | 1736 |
|
|
2022
Q2 | $270K | Sell |
4,673
-30
| -0.6% | -$1.73K | ﹤0.01% | 1737 |
|
|
2022
Q1 | $292K | Sell |
4,703
-1,951
| -29% | -$119K | ﹤0.01% | 1743 |
|
|
2021
Q4 | $474K | Buy |
6,654
+2,264
| +52% | +$164K | ﹤0.01% | 1444 |
|
|
2021
Q3 | $329K | Hold |
4,390
| – | – | ﹤0.01% | 1591 |
|
|
2021
Q2 | $339K | Sell |
4,390
-350
| -7% | -$26K | ﹤0.01% | 1536 |
|
|
2021
Q1 | $350K | Sell |
4,740
-359
| -7% | -$27.2K | ﹤0.01% | 1434 |
|
|
2020
Q4 | $358K | Buy |
5,099
+80
| +2% | +$5.07K | ﹤0.01% | 1316 |
|
|
2020
Q3 | $284K | Buy |
5,019
+200
| +4% | +$11.8K | ﹤0.01% | 1318 |
|
|
2020
Q2 | $281K | Sell |
4,819
-65
| -1% | -$3.54K | ﹤0.01% | 1248 |
|
|
2020
Q1 | $227K | Sell |
4,884
-1,196
| -20% | -$62.4K | ﹤0.01% | 1213 |
|
|
2019
Q4 | $340K | Buy |
6,080
+46
| +0.8% | +$2.4K | ﹤0.01% | 1172 |
|
|
2019
Q3 | $286K | Sell |
6,034
-1,248
| -17% | -$64K | ﹤0.01% | 1215 |
|
|
2019
Q2 | $390K | Sell |
7,282
-275
| -4% | -$14.3K | 0.01% | 1157 |
|
|
2019
Q1 | $417K | Sell |
7,557
-398
| -5% | -$21K | 0.01% | 1098 |
|
|
2018
Q4 | $374K | Buy |
7,955
+662
| +9% | +$34K | 0.01% | 1050 |
|
|
2018
Q3 | $434K | Buy |
7,293
+955
| +15% | +$55.7K | 0.01% | 1075 |
|
|
2018
Q2 | $347K | Buy |
6,338
+497
| +9% | +$25.3K | 0.01% | 1009 |
|
|
2018
Q1 | $287K | Sell |
5,841
-2
| -0% | -$102 | 0.01% | 1101 |
|
|
2017
Q4 | $276K | Sell |
5,843
-1,610
| -22% | -$75.5K | 0.01% | 1123 |
|
|
2017
Q3 | $372K | Sell |
7,453
-4,385
| -37% | -$208K | 0.01% | 911 |
|
|
2017
Q2 | $541K | Buy |
+11,838
| New | +$511K | 0.01% | 739 |
|
Other funds holding PBE
UCFA
GKWIM
YIA
MML Investors Services's PBE Position: Q1 2026 in Review
MML Investors Services sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2026, closing a stake of 2,497 shares — an estimated $205K sold.
MML Investors Services first reported a position in PBE in Q2 2017 and held it in 32 quarters. The position peaked at $541K in Q2 2017. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.
- MML Investors Services reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2026 after selling out during the quarter.
- MML Investors Services sold 2,497 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $205K.
- MML Investors Services first reported a position in Invesco Biotechnology & Genome ETF in Q2 2017 and held it in 32 quarters.
- MML Investors Services's Invesco Biotechnology & Genome ETF position peaked at $541K in Q2 2017.
- 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.
Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.